Compare AGRO & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGRO | AVLN |
|---|---|---|
| Founded | 2002 | 2011 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2011 | 2026 |
| Metric | AGRO | AVLN |
|---|---|---|
| Price | $10.54 | $23.74 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | $13.40 | ★ $61.80 |
| AVG Volume (30 Days) | ★ 532.3K | 294.8K |
| Earning Date | 11-12-2026 | 11-25-2026 |
| Dividend Yield | ★ 3.40% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $56.84 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.52 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.89 | $24.14 |
| 52 Week High | $15.89 | $40.17 |
| Indicator | AGRO | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 45.35 | 26.31 |
| Support Level | $9.82 | N/A |
| Resistance Level | $10.91 | $30.45 |
| Average True Range (ATR) | 0.35 | 1.69 |
| MACD | -0.02 | -0.32 |
| Stochastic Oscillator | 52.02 | 5.70 |
Adecoagro SA is a Luxembourg-based agricultural company. It is involved in a wide range of businesses, including farming crops and other agricultural products, dairy operations sugar, ethanol, energy production, and land transformation. The group operates in two lines of business, namely, Farming and Sugar, Ethanol and Energy. The Farming is further comprised of three reportable segments: Crops, Rice and Dairy. Sugar, Ethanol and Energy Segment, consists of cultivating sugarcane, which is processed in owned sugar mills, transformed into ethanol, sugar and electricity, in addition to biomethane and then marketed.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.